Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2)

被引：0
|
作者：
Blauvelt, Andrew [1 ]
Thyssen, Jacob P. [2 ]
Guttman-Yassky, Emma [3 ]
Bieber, Thomas [4 ]
Carrascosa, Jose Manuel [5 ]
Simpson, Eric [6 ]
Rosmarin, David [7 ]
Elmaraghy, Hany [8 ]
Meskimen, Eric [8 ]
Natalie, Chitra R. [8 ]
Liu, Zhuqing [8 ]
Xu, Chenjia [8 ]
Pierce, Evangeline [8 ]
Morgan-Cox, MaryAnn [8 ]
Silverberg, Jonathan, I [9 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR 97223 USA
[2] Univ Copenhagen, Bispebjerg Hosp, Copenhagen, Denmark
[3] Icahn Sch Med Mt Sinai, New York, NY USA
[4] Univ Hosp Bonn, Bonn, Germany
[5] UAB, Germans Trias i Pujol Univ Hosp, IGTP, Barcelona, Spain
[6] Oregon Hlth & Sci Univ, Portland, OR USA
[7] Tufts Univ, Sch Med, Boston, MA USA
[8] Eli Lilly & Co, Indianapolis, IN USA
[9] George Washington Univ, Sch Med & Hlth Sci, Washington, DC USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2023年 / 188卷
关键词：
monotherapy; atopic dermatitis; moderate-to-severe; lebrikizumab; interleukin (IL)-13;
D O I：
10.1093/bjd/ljac140.018
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
322
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials
    Mendes-Bastos, Pedro
    Ladizinski, Barry
    Guttman-Yassky, Emma
    Jiang, Ping
    Liu, John
    Prajapati, Vimal H.
    Simpson, Eric L.
    Vigna, Namita
    Teixeira, Henrique D.
    Barbarot, Sebastien
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (04) : 784 - 791
  • [22] The efficacy of whey associated with dodder seed extract on moderate-to-severe atopic dermatitis in adults: A randomized, double-blind, placebo-controlled clinical trial
    Mehrbani, Mehrzad
    Choopani, Rasool
    Fekri, Alireza
    Mehrabani, Mitra
    Mosaddegh, Mahmoud
    Mehrabani, Mehrnaz
    JOURNAL OF ETHNOPHARMACOLOGY, 2015, 172 : 325 - 332
  • [23] Upadacitinib improved patient-reported pruritus in moderate-to-severe atopic dermatitis: results from a phase 2B randomized, placebo-controlled trial
    Hong, C. -H.
    Wu, T.
    Calimlim, B.
    Teixeira, H.
    de Bruin-Weller, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 10 - 10
  • [24] Investigation on the clinical efficacy and safety of 0.1% tacrolimus ointment (Protopic®) in canine atopic dermatitis:: a randomized, double-blinded, placebo-controlled, cross-over study
    Marsella, R
    Nicklin, CF
    Saglio, S
    Lopez, J
    VETERINARY DERMATOLOGY, 2004, 15 (05) : 294 - 303
  • [25] Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial
    Blauvelt, Andrew
    Silverberg, Jonathan, I
    Lynde, Charles W.
    Bieber, Thomas
    Eisman, Samantha
    Zdybski, Jacek
    Gubelin, Walter
    Simpson, Eric L.
    Valenzuela, Fernando
    Criado, Paulo Ricardo
    Lebwohl, Mark G.
    Feeney, Claire
    Khan, Tahira
    Biswas, Pinaki
    DiBonaventura, Marco
    Valdez, Hernan
    Cameron, Michael C.
    Rojo, Ricardo
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 86 (01) : 104 - 112
  • [26] Maintenance of efficacy and safety with nemolizumab at week 48: results from two global phase 3 pivotal studies (ARCADIA-1 and ARCADIA-2) in patients with moderate-to-severe atopic dermatitis
    Silverberg, Jonathan, I
    Wollenberg, Andreas
    Legat, Franz J.
    Laquer, Vivian T.
    Armstrong, April W.
    Herranz, Pedro
    Naldi, Luigi
    Ahmad, Faiz
    Ulianov, Liliana
    Piketty, Christophe
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [27] Efficacy and safety of orismilast, a potent PDE4B/D inhibitor, in adults with moderate-to-severe atopic dermatitis: a phase 2b randomized, double-blind, placebo-controlled clinical trial (ADESOS)
    Silverberg, Jonathan
    Eichenfield, Lawrence
    Blauvelt, Andrew
    Irvine, Alan D.
    Langley, Richard
    Guttman, Emma
    Warren, Richard
    French, Lars
    Pedersen, Claus Bang
    Carlsson, Anna
    Jensen, Morten Lind
    Sommer, Morten O. A.
    Kjoller, Kim
    Simpson, Eric
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 68 - 69
  • [28] Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis
    Merola, Joseph F.
    Bagel, Jerry
    Almgren, Peter
    Ropke, Mads A.
    Lophaven, Katja W.
    Vest, Natacha Strange
    Grewal, Parbeer
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (01) : 71 - 78
  • [29] Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3
    Blauvelt, Andrew
    Gooderham, Melinda
    Bhatia, Neal
    Langley, Richard G.
    Schneider, Shannon
    Zoidis, John
    Kurbasic, Azra
    Armstrong, April
    Silverberg, Jonathan, I
    DERMATOLOGY AND THERAPY, 2022, 12 (11) : 2499 - 2516
  • [30] Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3
    Andrew Blauvelt
    Melinda Gooderham
    Neal Bhatia
    Richard G. Langley
    Shannon Schneider
    John Zoidis
    Azra Kurbasic
    April Armstrong
    Jonathan I. Silverberg
    Dermatology and Therapy, 2022, 12 : 2499 - 2516
12345